Loading
A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT05133882 by Sunshine Lake Pharma Co., Ltd., with 133 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Clifutinib Besylate.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Clifutinib, Sunshine Lake Pharma (HEC), Acute myeloid leukaemia.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.